GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Greenyn Biotechnology Co Ltd (ROCO:6846) » Definitions » Debt-to-Revenue

Greenyn Biotechnology Co (ROCO:6846) Debt-to-Revenue : 0.24 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Greenyn Biotechnology Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Greenyn Biotechnology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$159.9 Mil. Greenyn Biotechnology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was NT$53.7 Mil. Greenyn Biotechnology Co's annualized Revenue for the quarter that ended in Mar. 2024 was NT$904.6 Mil. Greenyn Biotechnology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.24.


Greenyn Biotechnology Co Debt-to-Revenue Historical Data

The historical data trend for Greenyn Biotechnology Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Greenyn Biotechnology Co Debt-to-Revenue Chart

Greenyn Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
0.25 0.18 0.10 0.12 0.25

Greenyn Biotechnology Co Quarterly Data
Dec19 Jun20 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.13 0.12 0.22 0.24

Competitive Comparison of Greenyn Biotechnology Co's Debt-to-Revenue

For the Biotechnology subindustry, Greenyn Biotechnology Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Greenyn Biotechnology Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Greenyn Biotechnology Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Greenyn Biotechnology Co's Debt-to-Revenue falls into.



Greenyn Biotechnology Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Greenyn Biotechnology Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(140.217 + 55.917) / 800.511
=0.25

Greenyn Biotechnology Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(159.925 + 53.69) / 904.644
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Greenyn Biotechnology Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Greenyn Biotechnology Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Greenyn Biotechnology Co (ROCO:6846) Business Description

Traded in Other Exchanges
N/A
Address
5th Floor, No 43 Keya Road, Daya District, Taichung, TWN
Greenyn Biotechnology Co Ltd has developed Insumate patented sequenced peptide, Antromax Antrodia cinnamomea mycelia, and Zymologist fermented liquid.

Greenyn Biotechnology Co (ROCO:6846) Headlines

No Headlines